Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | MYC | P01106 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27338933 | 0.86 | ALDH1A1 (0.52) | ALDH1A1HPGDHSD17B10KDM4EPOLB | |
| SCHEMBL5963706 | 0.82 | ALDH1A1 (0.57) | ALDH1A1HPGDHSD17B10KDM4EMYC | |
| SCHEMBL1549077 | 0.82 | ALDH1A1 (0.57) | ALDH1A1HPGDHSD17B10KDM4EMYC | |
| SCHEMBL2258690 | 0.82 | HAAO (0.40) | ALDH1A1HPGDHSD17B10KDM4EMYC | |
| SCHEMBL5988902 | 0.81 | ALDH1A1 (0.55) | ALDH1A1HPGDHSD17B10KDM4EMYC | |
| SCHEMBL2227278 | 0.81 | ALDH1A1 (0.55) | ALDH1A1HPGDHSD17B10KDM4EMYC | |
| SCHEMBL27409195 | 0.81 | ALDH1A1 (0.55) | ALDH1A1HPGDHSD17B10KDM4EMYC | |
| SCHEMBL7025449 | 0.81 | ALDH1A1 (0.55) | ALDH1A1HPGDHSD17B10KDM4EMYC | |
| SCHEMBL2340668 | 0.81 | KDM4E (0.55) | ALDH1A1HPGDHSD17B10KDM4EMYC | |
| SCHEMBL3540201 | 0.80 | ALDH1A1 (0.47) | ALDH1A1HSD17B10KDM4EMYCKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976059-B2 | Isoindolin-1-on derivative, method for preparing same, and pharmaceutical composition comprising same as effective component for preventing or treating cancer | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-05-07 | — | — | US | disclosed |
| CN-112839937-B | Isoindolin-1-one derivatives, preparation method and application thereof | 韩国化学研究院 | 2023-08-22 | — | — | CN | disclosed |
| EP-3838898-B1 | ISOINDOLIN-1-ONE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS AN EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2023-06-07 | — | — | EP | disclosed |
| US-20210332029-A1 | ISOINDOLIN-1-ON DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-10-28 | — | — | US | disclosed |
| EP-3838898-A1 | ISOINDOLIN-1-ON DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | Korea Research Institute of Chemical Technology (KR) | 2021-06-23 | — | — | EP | disclosed |
| CN-112839937-A | Isoindolin-1-one derivative, method for preparing same, and pharmaceutical composition for preventing or treating cancer comprising same as effective component | 韩国化学研究院 | 2021-05-25 | — | — | CN | disclosed |
| EP-2865669-B1 | NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF | SAMJIN PHARM CO LTD (KR) | 2021-04-28 | — | — | EP | disclosed |
| US-10807946-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| WO-2020036386-A1 | ISOINDOLIN-1-ON DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | 한국화학연구원 | 2020-02-20 | — | — | WO | disclosed |
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-5175164-A | Hypotensive agents | MERCK & CO., INC. (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0517357-A1 | Angiotensin II antagonists incorporating a substituted indole or dihydroindole | MERCK & CO. INC. (US) | 1992-12-09 | — | — | EP | disclosed |
| EP-0508723-A1 | Angiotensin II antagonists incorporating an indole or dihydroindole | MERCK & CO. INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| US-5151435-A | Hypotensive agents, glaucoma and cognition activators | MERCK & CO., INC. (US) | 1992-09-29 | — | — | US | disclosed |
| EP-0110405-B1 | ANTIINFLAMMATORY/ANTIALLERGIC COMPOUNDS | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) (US) | 1990-12-27 | — | — | EP | disclosed |
| US-4866076-A | THROMBOXANE ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-09-12 | — | — | US | disclosed |
| EP-0300725-A1 | Tetrahydroisoquinolin-2-yl derivatives as thromboxane A2 antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-01-25 | — | — | EP | disclosed |
| US-4778931-A | ENZYME INHIBITORS | USV PHARMACEUTICAL CORPORATION (US) | 1988-10-18 | — | — | US | disclosed |
| US-4567184-A | Certain aryl or hetero-aryl derivatives of 1-hydroxy-pentane or 1-hydroxy-hexane which are useful for treating inflammation and allergies | USV PHARMACEUTICAL CORPORATION (US) | 1986-01-28 | — | — | US | disclosed |
| EP-0110405-A2 | Antiinflammatory/antiallergic compounds | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) (US) | 1984-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332029-A1 | ISOINDOLIN-1-ON DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | EGFR, TP53, BRCA1 | ALDH1A1 1073/4885HPGD 302/4885HSD17B10 2221/4885 |
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | ALDH1A1 4644/4885HPGD 2632/4885HSD17B10 1117/4885 |
| US-10807946-B2 | Antagonists of the glucagon receptor | GLP1R, GCGR, GPR119 | ALDH1A1 4657/4885HPGD 2765/4885HSD17B10 1104/4885 |
| US-11976059-B2 | Isoindolin-1-on derivative, method for preparing same, and pharmaceutical composition comprising same as effective component for preventing or treating cancer | EGFR, TP53, BRCA1 | ALDH1A1 1073/4885HPGD 302/4885HSD17B10 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.